(Values in U.S. Thousands) | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 | Jun, 2020 |
Sales | 0 | 0 | 0 | 0 | 0 |
Sales Growth | unch | unch | unch | unch | unch |
Net Income | -5,619 | -6,321 | -17,807 | -20,119 | -5,382 |
Net Income Growth | +11.11% | +64.50% | +11.49% | -273.84% | -300.46% |
Revive Therapeutics Ltd (RVV.CN)
0.0100 unch (unch) 09:31 ET [CNSX]
0.0050 x 14,660,000 0.0100 x 3,131,000
Realtime by (Cboe BZX)
0.0050 x 14,660,000 0.0100 x 3,131,000
Realtime - - (-) -
for Mon, Jan 27th, 2025
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.
Fiscal Year End Date: 06/30